The multiomics research service provider Novogene Europe has launched its Untargeted Metabolomics Service through its Cambridge Omics Centre.
The new capability, the company says, will help researchers across the UK and Europe to connect molecular data with biological function, through the addition of metabolite-level insights to genomics, transcriptomics, microbiome and broader life sciences studies.
The Untargeted Metabolomics Service profiles small-molecule changes that sit closer to phenotype, enabling researchers to explore the biochemical activity underlying complex biological systems.
Built around Thermo Fisher Scientific's Vanquish UHPLC and its Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry, the new liquid chromatography–mass spectrometry (LC-MS) workflow uses an extensive reference library, offering comprehensive, high-resolution metabolite profiling across suitable biological sample types.
Novogene noted that this will strengthen its expertise in genomics, transcriptomics, sequencing and bioinformatics, helping researchers gain deeper insights into disease mechanisms, microbiome interactions, treatment responses and biomarker discovery.
The launch of Metabolomics is the first in what the company described as a "broader phase of capability expansion" at its Cambridge Omics Centre at the Bio-Innovation Centre in Cambridge, UK.
The firm added that the launch reinforces its long-term commitment to supporting customers from experimental planning and data generation through to bioinformatics and biological interpretation.
"Launching Untargeted Metabolomics through our Cambridge Omics Centre is an important step in strengthening Novogene Europe’s multiomics capabilities and supporting researchers with a more integrated view of biology," said Tingting Zhou, VP of Novogene Europe.
As research questions become more complex, customers increasingly need to connect genomic and transcriptomic information with functional biochemical insight.
"Metabolomics adds a powerful layer to this picture, helping researchers explore disease mechanisms, microbiome interactions, treatment response and pathway-level biology."
"This launch also reflects Novogene’s continued evolution from a trusted sequencing service provider into a broader multiomics partner."
During our 15th anniversary year, it is especially meaningful to expand our capabilities in Cambridge and continue supporting academic, biotech and biopharma researchers with high-quality data generation, bioinformatics and scientific expertise across Europe.
"Cambridge has a long-standing reputation as a centre for life science innovation and access to advanced omics capabilities is an important part of that ecosystem," added David Chaplin, General Manager of the Bio-Innovation Centre.
We welcome Novogene Europe’s continued investment in the Cambridge Omics Centre and its development of metabolomics services to support researchers and companies working at the forefront of biological discovery.
